In the malignant cells within the tumour, NRF2 activation will contribute to the efficacy of Sotorasib and Adagrasib through upregulation of NISP gene expression, which will promote immune cell infiltration into the tumour and anti-cancer immune surveillance. Here, NFE2L2 is linked to cancer.